Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.
Frequently asked questions
What sector does Dianthus Therapeutics Inc. (DNTH) operate in?
Dianthus Therapeutics Inc. belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Dianthus Therapeutics Inc. (DNTH) current stock price?
As of the latest data, Dianthus Therapeutics Inc. stock price is $109.60, with a previous close of $112.41. Dianthus Therapeutics Inc. lost -$2.81 in the last trading session, representing a -2.5% loss.
What is Dianthus Therapeutics Inc. (DNTH) current market capitalization?
Dianthus Therapeutics Inc. market cap is approximately 5.99 billion.
What is Dianthus Therapeutics Inc. (DNTH) Earnings Per Share (EPS)?
The trailing EPS is -$4.24, and the forward EPS is -$4.74.
What is Dianthus Therapeutics Inc. (DNTH) EBITDA?
Dianthus Therapeutics Inc. EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -50.18 million.
Does Dianthus Therapeutics Inc. (DNTH) pay dividends?
No. Dianthus Therapeutics Inc. does not pay a dividend.
How did Dianthus Therapeutics Inc. (DNTH) perform in its most recent earnings report?
In the last report (June 30, 2026), Dianthus Therapeutics Inc. posted an EPS surprise of 3.23% and a revenue surprise of 205.93%.
What is Dianthus Therapeutics Inc. (DNTH) beta (volatility) score?
Dianthus Therapeutics Inc. has a beta of 0.082, indicating lower volatility than the overall market.
